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EDITORIAL
Discrepant Atrial Fibrillation Guidelines
Antonis S. Manolis, MD
Evagelismos General Hospital of Athens, Athens, Greece
Recently, cardiological societies in Europe (ESC), US 
and Canada (CCS) have updated their guidelines for atrial 
fibrillation (AF). However, there are several discrepancies 
which have been identified and discussed. Among them, 
the following are the most blatant ones. 
• Anticoagulation. Atrial fibrillation confers a 5-fold 
increase in the risk of stroke if left without anticoagulation 
therapy and a 2-fold increase in the risk of death from 
such thromboembolic strokes. The US guidelines 
recommend anticoagulation for a patient with a CHADS2 
score of 2, and either aspirin or anticoagulation for a 
patient with a CHADS2 score of 1, while the CCS and 
ESC guidelines recommend anticoagulation for a patient 
with 1 risk factor(s). The new anticoagulants are taken 
into consideration by the CCS guidelines, recommending 
dabigatran instead of vitamin K antagonists (VKA). The 
ESC guidelines make recommendations for future use of 
dabigatran (when approved in the EU) depending on the 
risk of bleeding; for low-risk patients it may be 
considered, while for higher risk patients the lower dose of 
110 mg of dabigatran may be considered. Also patients 
with a CHADS2 score of 1 may receive the lower dose 
(110 mg) of dabigatran. The US guidelines issued an 
update for dabigatran, indicating that it is a useful 
alternative to VKA. The FDA has approved only the 
higher dabigatran dose (150 mg bid) and a half-dose (75 
mg bid) for patients with renal insufficiency. In the near 
future, the guidelines need also consider the newer 
anticoagulants, the active factor Xa inhibitors, 
rivaroxaban and apixaban, which are being tested in new 
randomized anticoagulation trials. Aspirin practically 
plays no role in thromboembolic prophylaxis in the ESC 
guidelines, but there is still a role in the US and CCS 
guidelines. The US and ECS guidelines recommend 
clopidogrel plus aspirin for patients who refuse warfarin 
therapy, while the CCS guidelines recommend dabigatran. 
In an attempt for safer, more effective anticoagulation 
and to establish better risk profiles for assessing the 
likelihood of stroke in patients with AF by refining the use 
of CHADS2 score, the ESC guidelines introduced a new 
(deemed more sensitive) system called CHA2DS2-VASc, 
by adding in other risk factors. These include additional 
score points for specific age categories and for the 
presence of vascular disease and female gender. 
Furthermore, they linked to this a new score, HAS-BLED, 
for assessing bleeding risk. 
• Rate and Rhythm Control. ESC guidelines recommend 
lenient rate control with a resting heart rate of <110 bpm 
(class IIa, level of evidence B) or stricter rate control for 
persisting symptoms or tachycardiomyopathy with a 
resting heart rate of < 80 bpm and heart rate during 
moderate exercise <110 bpm (also class IIa indication, 
level of evidence B).  The US guidelines also accept 
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lenient heart rate control in patients with LVEF > 40%, 
but designate strict rate control as class III (of no benefit). 
In contrast, CCS guidelines recommend a target resting 
heart rate of <100 bpm. 
Drugs to achieve rate control include beta-blockers, 
(non-hydropyridine) calcium blockers and digoxin. In 
addition, the ESC and CCS guidelines accept dronedarone 
for rate control in non-permanent AF (barring patients 
with NYHA III-IV or unstable heart failure); however, this
needs to be proven in future studies. Amiodarone also 
constitutes second choice for rate control in both
guidelines. The US guidelines do not provide 
recommendations for rate control. The CCS guidelines 
recommend atrio-ventricular (AV) junction ablation with 
implantation of a pacemaker for symptomatic patients 
with uncontrolled ventricular rates during AF despite 
maximally tolerated combined drug therapy. ESC 
guidelines recommend performing AV junction ablation in 
patients who are candidates for cardiac resynchronization 
therapy (CRT) or for CRT non-responders who are not 
paced in a biventricular mode due to fast AF. 
For rhythm control, there is general agreement in the 
guidelines that the choice of antiarrhythmic therapy 
depends on the presence of underlying structural heart 
disease. Flecainide, propafenone and sotalol should be 
used only in patients with a structurally and functionally 
normal heart. Thus, amiodarone remains the sole relatively 
safe (less proarrhythmic) drug for use in patients with 
ischemic or non-ischemic cardiomyopathy with low 
ejection fraction. The US and ECS guidelines recommend 
avoidance of class IC antiarrhythmic drugs and sotalol in 
patients with left ventricular hypertrophy, while the CCS 
recommend avoidance of these drugs if there are 
repolarization abnormalities on the ECG. 
All three guidelines included the new antiarrhythmic 
drug dronedarone, which was recently approved, into the 
recommendations. All agree that dronaderone should not 
be employed in patients with NYHA class III-IV or 
recently decompensated heart failure, per the results of the 
ANDROMEDA trial. However, there appear to be more 
problems with this new drug after market approval and 
more data are awaited for its safety. None of the 
guidelines make clear recommendations on the new atrial 
selective antiarrhythmic drug vernakalant, which has 
recently become available (intravenous form) for 
cardioversion of recent-onset AF; the ESC guidelines 
include it in a table and a footnote for future use for acute 
termination (pharmacological conversion) when approved. 
• Symptoms. The ESC guidelines introduced a new 
symptom score for arrhythmias, the EHRA score, like the 
CCS class for angina or the NYHA class for heart failure. 
The EHRA score is designed to provide a classification of 
a patient's symptomatic status, for better and more specific
treatment which is symptom-dependent. 
• Radiofrequency Ablation. In all guidelines, ablation is 
generally reserved for symptomatic patients with 
paroxysmal lone AF (little or no structural heart disease), 
who have failed at least one trial of antiarrhythmic 
therapy. There are still some differences among the 
guidelines regarding this approach. The CCS guidelines 
consider the failure of 2 antiarrhythmic drugs as a strong 
recommendation for catheter ablation. The US guidelines 
recommend catheter ablation for patients with 
symptomatic paroxysmal AF who have failed an 
antiarrhythmic drug (class I indication, level of evidence 
A), when performed in experienced centers and in patients 
with normal or mildly dilated left atria, normal, or mildly 
reduced LV function and no severe pulmonary disease. 
The CCS and ESC guidelines make no mention of the left 
atrial size. Both the US and ESC guidelines distinguish 
between paroxysmal and persistent AF, whereas the CCS 
recommendations do not separate AF. The ESC guidelines 
consider catheter ablation for symptomatic AF after 
failure of an antiarrhythmic drug as class IIa indication 
(level of evidence A) and of persistent AF as IIa (level of 
evidence B). In patients with heart failure, ablation may be 
considered when antiarrhythmic therapy, amiodarone 
included, has failed (class IIb, level of evidence B).
In addition to the three categories of AF (paroxysmal -
AF lasting <7 days; persistent AF -7 days to 1 year; and 
permanent AF), the ESC guidelines added another 
category, the long-standing persistent AF, defined as AF 
lasting > 1 year, creating a new category of patients felt to 
be candidate for ablation therapy. 
• Other Issues. The ESC guidelines attempt to give advice 
on a number of "special situations”, such as in athletes 
with AF, whereby drug treatment is often difficult, 
suggesting a pill-in-the pocket approach or ablation for 
more definitive therapy; also in patients with hypertophic 
cardiomyopathy, hyperthyroidism and pulmonary disease. 
The same guidelines provide recommendations on the so-
called "upstream" therapy (use of ACE inhibitors, 
angiotensin-receptor blockers-ARBs, and statins), 
prescribed in an attempt to prevent the deterioration of 
AF. The CCS guidelines emphasize treatment of 
comorbidities such as hypertension and obstructive sleep 
apnea. Finally, a list of triggers and causes of AF are 
listed in Table 1. 
13 
 
Table 1. Causes, Triggers and Risk Factors for Atrial 
Fibrillation (AF) 
Hypertension (esp. with associated LVH)
Diabetes
Ischemic heart disease
Cardiomyopathy (dilated and hypertrophic)
Heart Failure
Peri-myocarditis/pericardial effusion/constrictive pericarditis
Valvular heart disease
Congenital heart disease
Prior heart surgery
Bradyarrhythmias: sinus node dysfunction
Preexcitation syndromes / other supraventricular 
tachycardias / Atrial flutter
Thyroid disease
Chronic pulmonary disease 
CVA
Obesity
Viral infections
Pneumonia
Pulmonary embolism
Sleep apnea
GI disorders
Sepsis
Electrolyte disturbances
Older age* / Race **
Alcohol, caffeine, nicotine
Drugs: beta-2 agonists, amphetamines, decongestants, 
xanthines, cocaine, glucocorticoids
Physical / emotional stress
Family history / genetic factors (mutations or single 
nucleotide polymorphisms)
Lone / idiopathic AF (5-10%)
________________________________________
CVA = cerebrovascular accident; GI = gastrointentistinal; 
LVH = left ventricular hypertrophy
* age-dependent / **more common in whites than in blacks 
(“AF paradox”) 
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